LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X

Find the latest Drugs in Development and Pipeline Prospector News of Antares Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Antares Pharma
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
100 Princeton South Suite 300 Ewing, New Jersey 08628
Telephone
Telephone
(609) 359-3020
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando (testosterone undecanoate).


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Halozyme Therapeutics

Deal Size: $960.0 million Upfront Cash: $960.0 million

Deal Type: Acquisition May 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLANDO® is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone in adult males.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Lipocine

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The combination of Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Halozyme Therapeutics

Deal Size: $960.0 million Upfront Cash: $960.0 million

Deal Type: Acquisition April 13, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLANDO ® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lipocine

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The results of the Phase I study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile and also demonstrated that ATRS-1902 was safe and well-tolerated for the treatment of acute adrenal insufficiency.


Lead Product(s): Hydrocortisone

Therapeutic Area: Endocrinology Product Name: ATRS-1902

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the definitive agreements, Assertio acquired Otrexup from Antares in a partially seller financed transaction inclusive of working capital investments. Otrexup is a once weekly single dose auto-injector containing a prescription medicine, methotrexate.


Lead Product(s): Methotrexate

Therapeutic Area: Immunology Product Name: Otrexup

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Assertio Holdings

Deal Size: $44.0 million Upfront Cash: $18.0 million

Deal Type: Acquisition December 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In granting tentative approval, the FDA concluded that TLANDO® met all required efficacy, quality and safety standards necessary for approval and will be eligible for final approval and marketing in the U.S.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Lipocine

Deal Size: $25.0 million Upfront Cash: $11.0 million

Deal Type: Licensing Agreement October 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.


Lead Product(s): Hydrocortisone

Therapeutic Area: Endocrinology Product Name: ATRS-1902

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.


Lead Product(s): Desmopressin Acetate

Therapeutic Area: Urology Product Name: Nocdurna

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: Ferring Pharmaceuticals

Deal Size: $25.0 million Upfront Cash: $5.0 million

Deal Type: Licensing Agreement October 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo® featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary,


Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY